We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
C4x Discovery Holdings Plc | LSE:C4XD | London | Ordinary Share | GB00BQQ2RV18 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 12.00 | 10.30 | 10.80 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1.71M | -11.11M | -0.0441 | -2.72 | 30.27M |
Date | Subject | Author | Discuss |
---|---|---|---|
20/6/2023 07:36 | Good to see a natural progression in Senior Management, I have no doubt with Clive's successes and C4XD's potential that he will attract a very strong CEO for the company. | copandrobber | |
15/6/2023 11:59 | artificial intelligence will have an impact on this company, positive or negative? | astorcourt | |
14/6/2023 05:51 | https://parkinsonsne | bloomberg2 | |
13/6/2023 23:47 | I dont know if anyone has noticed but PatientSeek could be a game changer for C4XD, on top of the potential drug revenues further down the line. In the test they were able to tell, using a person's DNA, which Parkinsons treatment would work best for each patient. Personal medication - the Holy Grail - with potentially massive life and cost savings for the NHS, etc. We should be discussing this as well. | alloa2003 | |
12/6/2023 16:39 | Another good day today. Nice and steady and decent volume | copandrobber | |
12/6/2023 11:36 | If this is the third wave we could be in for a large move up. We’re in breakout territory for sure. | imnotspartacus | |
12/6/2023 07:57 | Car sounds really positive could be multibagger from here. | imnotspartacus | |
10/6/2023 09:27 | I'm convinced it is. It's clear there has been a seller in this stock for a long time. Every time good news was announced, it was sold into very hard despite clear value creation from the company. Prob a fund redemption. There seems to be nothing in the way now, I bid for some more stock on Friday and didn't have my hand bitten off like some many times over the last few months, in fact I had to work for it. This is back to 25p in the v short term and then expect a re rating as milestone payments are made. They do t need to fundraise and their portfolio just keeps becoming more and more valuable. If they decide to divest one of these in the future, this could see a rerate to £1 and beyond. It seems that Clive and his team are extremely well disciplined, they keep their heads down and get on with it!! V v strong BUY | copandrobber | |
09/6/2023 09:02 | Is this a breakout? | imnotspartacus | |
08/6/2023 14:32 | With you 100% on that !! Way over due news on toxicology report | bloomberg2 | |
08/6/2023 13:47 | Agreed. We should get news on milestone payments soon. Looking v good. 25p will be next level. | copandrobber | |
08/6/2023 13:12 | ETX work closely with C4XD !!! Something cooking | bloomberg2 | |
06/6/2023 21:32 | the deal with Indivior for the orexin compound is more than 5 years old and we haven't had the Phase 1 results yet, what's happening? | davemac3 | |
01/6/2023 07:39 | Yet another great result! | copandrobber | |
05/5/2023 21:10 | This has been a bit leaky in the past so wouldn’t surprise me to see news in the not too distant future. | davemac3 | |
05/5/2023 11:38 | Here we go!! Retrace!! 25p+ coming shortly! | copandrobber | |
26/4/2023 10:07 | Very positive half year results presentation. Co is confident they have another diamond in the form of the A4B7 programme for the treatment of inflammatory bowel disease which should result in another major out-licence deal in approx 12-18 months | t0pgrader | |
26/4/2023 09:40 | This is such a good buy at this price! If anyone ventures onto this board, have a look at their half year results and then enjoy buying a great company that is totally overlooked and undervalued! This will get taken out or taken private at a significantly higher price than it is today!! You heard it here first!! | copandrobber | |
22/2/2023 07:23 | https://twitter.com/ | bloomberg2 | |
19/1/2023 14:10 | that RNS looks like an attempt to shore up the share price. We need some milestone payments from the partnered projects or I can see another fund raise in the not too distant future. | davemac3 | |
18/1/2023 14:38 | being a betting man this will get taken private this year ! to bombed out ! plenty in the pipe line ! owned buy 3/4 funds most of it ! see a 25- 30p bid and they will run it for 1/2 years and sell out !!TCM all over again | fewmonster | |
17/1/2023 16:52 | bit of selling today, it's about time we heard from Indivior on the Orexin drug | davemac3 | |
20/12/2022 12:45 | How long a new drug takes to go through clinical trials There is no typical length of time it takes for a drug to be tested and approved. It might take 10 to 15 years or more to complete all 3 phases of clinical trials before the licensing stage. But this time span varies a lot. | noirua | |
19/12/2022 21:18 | alloa20032 Dec '22 - 18:13 - 2839 of 2842 0 1 0 While a lot of the potential income is heavily loaded towards the backend, there is still some potentially huge income to come well before these compounds even get to market. I am not sure of your 6 year estimate - where did you get this from? I have not seen it referenced by the company at any stage. However, I may have missed it. They haven't completed phase 1 on anything yet, I am basing it on the at least 10 year time span to develop a drug. | davemac3 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions